FIELD: immunology; medical biotechnology; bioengineering.
SUBSTANCE: method for obtaining a vaccine against respiratory infections is described. Influenza viruses of subtypes A (H1N1), A (H3N2), B/Yamagata lineage, B/Victoria lineage are separately cultivated in developing chicken embryos, followed by separation of the virus-containing allantoic fluid, its concentration and purification. The virus is inactivated and split, followed by centrifugation, ultrafiltration and production of monovalents for each strain, as well as the cultivation of a cell line producing the recombinant protein of the SARS-CoV-2 virus - RBD-Fc with selection and clarification of the culture fluid containing RBD-Fc. Chromatographic purification is carried out to obtain monovalent. An adjuvant is added to each monovalent separately. Betulin is used as an adjuvant at an antigen:adjuvant ratio of 1:1.25 to 1:12.5. Then the monovaccines are combined into a combined vaccine.
EFFECT: invention expands the arsenal of means for the prevention of respiratory infections, in particular influenza and SARS-CoV-2.
2 cl, 2 dwg, 7 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF PRODUCING TETRAVALENT SUBUNIT INFLUENZA VACCINE | 2019 |
|
RU2740751C1 |
| HYBRID GENE CONSISTING OF THE RBD RECEPTOR OF THE SURFACE PROTEIN S OF SARS-CoV-2 CORONAVIRUS, S14P5 AND S21P2 EPITOPES, Fc FRAGMENT, FOR OBTAINING A RECOMBINANT ANTIGEN AND ITS USE AS PART OF A VACCINE COMPOSITION AGAINST CORONAVIRUS INFECTION | 2022 |
|
RU2795160C1 |
| METHOD FOR OBTAINING A TETRAVALENT VACCINE FOR THE PREVENTION OF INFLUENZA | 2020 |
|
RU2754398C1 |
| METHOD FOR PREPARATION OF BETULIN FOR USE AS ADJUVANT IN VACCINE AGAINST SARS-COV-2 CORONAVIRUS | 2020 |
|
RU2749193C1 |
| GENE CONSTRUCT FOR THE EXPRESSION OF RECOMBINANT PROTEINS BASED ON THE SEGMENT OF THE SARS-COV-2 S-PROTEIN, INCLUDING RBD AND SD1, FUSED WITH THE FC FRAGMENT OF IGG, A METHOD OF OBTAINING RECOMBINANT PROTEINS, ANTIGENS AND ANTIGENIC COMPOSITIONS FOR THE INDUCTION OF LONG-TERM ANTIBODY AND CELLULAR IMMUNITY AGAINST SARS-CO-2 | 2021 |
|
RU2802825C2 |
| VACCINE AGAINST INFLUENZA TYPE A, INFLUENZA TYPE B AND COVID-19 | 2021 |
|
RU2751485C1 |
| EXPRESSION VECTOR BASED ON HUMAN ADENOVIRUS 19 SEROTYPE AND METHOD OF ITS APPLICATION | 2023 |
|
RU2811791C1 |
| ARTIFICIAL GENE CODING A BICISTRONIC STRUCTURE FORMED BY RECEPTOR-BINDING DOMAIN SEQUENCES OF THE GLYCOPROTEIN S OF THE SARS-COV-2 CORONAVIRUS, P2A-PEPTIDE AND GLYCOPROTEIN G VSV, RECOMBINANT PLASMID PSTEM-RVSV-STBL_RBD_SC2, PROVIDING EXPRESSION OF ARTIFICIAL GENE, AND A RECOMBINANT STRAIN OF VESICULAR STOMATITIS VIRUS RVSV-STBL_RBD_SC2, USED TO CREATE A VACCINE AGAINST SARS-COV-2 CORONAVIRUS | 2020 |
|
RU2733831C1 |
| RECOMBINANT INFLUENZA VIRUS INTENDED FOR THE PREVENTION OF COVID-19 AND INFLUENZA, METHOD OF ITS PRODUCTION AND USE | 2022 |
|
RU2802058C1 |
| METHOD OF PRODUCING ANTIGEN OR ANTIGENS FOR PRODUCTION OF INFLUENZA VACCINE AND A VACCINE BASED ON IT | 2019 |
|
RU2710239C1 |
